{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:17:05Z","timestamp":1794665825739,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cerebrotendinous xanthomatosis (CTX) is a rare treatable bile acid disorder caused by homozygous or compound heterozygous variants in <jats:italic>CYP27A<\/jats:italic>, a gene that encodes the mitochondrial enzyme sterol 27-hydroxylase (CYP27A1). CYP27A1 facilitates the production of both cholic acid (CA) and chenodeoxycholic acid (CDCA). Deficiencies in CYP27A1 limit the production of both CA and CDCA, leading to multisystemic cholestanol deposition in membranes, including those of neurons, smooth muscle cells, tendons, and the eye. Because of increased concentrations of cholestanol, a byproduct of cholesterol metabolism, in the brain, cognitive decline develops as a hallmark of CTX. First-line treatment approaches for CTX include off-label prescribed CDCA to reduce serum cholestanol levels. Despite its effectiveness, the success of CDCA administration relies on early diagnosis and low disability scores at the time of initiation. Administration when neurological symptoms arise late in the diagnostic process can lead to worse outcomes, including higher mortality. US Food &amp; Drug Administration-approved CA represents an alternative treatment for CTX. CA reduced cholestanol levels in CSF and blood while also reducing bile acid synthesis and excretion of bile alcohols in the urine. Importantly, outcomes with CA therapy are indistinguishable from those mediated by CDCA therapy and are associated with significantly fewer adverse effects. CA is used as an alternative therapy in patients who cannot tolerate CDCA due to its negative effects. Data from studies on CA strongly support the improvement of liver function, which is likely to be at the crux of secondary pathology, including neurological dysfunction. Because no consensus has been published on the treatment of CTX, Stelten et al (Orphanet J Rare Dis 16:353, 2021) a need exists for a direct comparison of the two approaches.<\/jats:p>","DOI":"10.1186\/s13023-025-03889-9","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T09:46:24Z","timestamp":1753782384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cholic acid as a treatment for cerebrotendinous xanthomatosis: a comprehensive review of safety and efficacy"],"prefix":"10.1186","volume":"20","author":[{"given":"Gary","family":"Pasternack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdyal","family":"Kalsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"1","key":"3889_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13023-021-01980-5","volume":"16","author":"BML Stelten","year":"2021","unstructured":"Stelten BML, Dotti MT, Verrips A, et al. Expert opinion on diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified Delphi study. Orphanet J Rare Dis. 2021;16(1):353. https:\/\/doi.org\/10.1186\/s13023-021-01980-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3889_CR2","unstructured":"Carson BE, De Jesus O. Cerebrotendinous Xanthomatosis. StatPearls. 2023."},{"key":"3889_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","volume":"72","author":"DW Russell","year":"2003","unstructured":"Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137\u201374. https:\/\/doi.org\/10.1146\/annurev.biochem.72.121801.161712.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"3889_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1172\/JCI109275","volume":"63","author":"G Salen","year":"1979","unstructured":"Salen G, Shefer S, Cheng FW, Dayal B, Batta AK, Tint GS. Cholic acid biosynthesis: the enzymatic defect in cerebrotendinous xanthomatosis. J Clin Invest. 1979;63(1):38\u201344. https:\/\/doi.org\/10.1172\/JCI109275.","journal-title":"J Clin Invest"},{"issue":"1","key":"3889_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1006\/bbrc.1998.9497","volume":"256","author":"K Inoue","year":"1999","unstructured":"Inoue K, Kubota S, Seyama Y. Cholestanol induces apoptosis of cerebellar neuronal cells. Biochem Biophys Res Commun. 1999;256(1):198\u2013203. https:\/\/doi.org\/10.1006\/bbrc.1998.9497.","journal-title":"Biochem Biophys Res Commun"},{"issue":"Pt 5","key":"3889_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/brain\/123.5.908","volume":"123","author":"A Verrips","year":"2000","unstructured":"Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain. 2000;123(Pt 5):908\u201319. https:\/\/doi.org\/10.1093\/brain\/123.5.908.","journal-title":"Brain"},{"issue":"1\u20133","key":"3889_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0344-0338(80)80166-X","volume":"170","author":"DH Boehme","year":"1980","unstructured":"Boehme DH, Sobel HJ, Marquet E, Salen G. Liver in cerebrotendinous xanthomatosis (CTX)\u2013a histochemical and EM study of four cases. Pathol Res Pract. 1980;170(1\u20133):192\u2013201. https:\/\/doi.org\/10.1016\/S0344-0338(80)80166-X.","journal-title":"Pathol Res Pract"},{"issue":"6","key":"3889_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1023\/a:1021211520034","volume":"25","author":"PT Clayton","year":"2002","unstructured":"Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2002;25(6):501\u201313. https:\/\/doi.org\/10.1023\/a:1021211520034.","journal-title":"J Inherit Metab Dis"},{"key":"3889_CR9","unstructured":"Setchell K, O\u2019Connel N, Russell D, al e. A unique case of cerebrotendinous xanthomatosis presenting in infancy with cholestatic liver disease further highlights bile acid synthetic defects as an important category of metabolic liver disease. 2000:"},{"issue":"24","key":"3889_CR10","doi-asserted-by":"publisher","first-page":"14805","DOI":"10.1074\/jbc.273.24.14805","volume":"273","author":"H Rosen","year":"1998","unstructured":"Rosen H, Reshef A, Maeda N, et al. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol Chem. 1998;273(24):14805\u201312. https:\/\/doi.org\/10.1074\/jbc.273.24.14805.","journal-title":"J Biol Chem"},{"key":"3889_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-014-0179-4","volume":"9","author":"S Nie","year":"2014","unstructured":"Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9:179. https:\/\/doi.org\/10.1186\/s13023-014-0179-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3889_CR12","doi-asserted-by":"publisher","first-page":"1049850","DOI":"10.3389\/fneur.2022.1049850","volume":"13","author":"PR Nobrega","year":"2022","unstructured":"Nobrega PR, Bernardes AM, Ribeiro RM, et al. Cerebrotendinous Xanthomatosis: a practice review of pathophysiology, diagnosis, and treatment. Front Neurol. 2022;13:1049850. https:\/\/doi.org\/10.3389\/fneur.2022.1049850.","journal-title":"Front Neurol"},{"issue":"4","key":"3889_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10072-019-04169-8","volume":"41","author":"A Verrips","year":"2020","unstructured":"Verrips A, Dotti MT, Mignarri A, Stelten BML, Verma S, Federico A. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies. Neurol Sci. 2020;41(4):943\u20139. https:\/\/doi.org\/10.1007\/s10072-019-04169-8.","journal-title":"Neurol Sci"},{"key":"3889_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13070979","author":"RM Ribeiro","year":"2023","unstructured":"Ribeiro RM, Vasconcelos SC, Lima P, et al. Pathophysiology and Treatment of lipid abnormalities in cerebrotendinous xanthomatosis: an integrative review. Brain Sci. 2023. https:\/\/doi.org\/10.3390\/brainsci13070979.","journal-title":"Brain Sci"},{"issue":"20","key":"3889_CR15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJM198705143162002","volume":"316","author":"G Salen","year":"1987","unstructured":"Salen G, Berginer V, Shore V, et al. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med. 1987;316(20):1233\u20138. https:\/\/doi.org\/10.1056\/NEJM198705143162002.","journal-title":"N Engl J Med"},{"issue":"6","key":"3889_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10545-017-0093-8","volume":"40","author":"G Salen","year":"2017","unstructured":"Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis. 2017;40(6):771\u201381. https:\/\/doi.org\/10.1007\/s10545-017-0093-8.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3889_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ymgme.2015.10.010","volume":"116","author":"V Appadurai","year":"2015","unstructured":"Appadurai V, DeBarber A, Chiang PW, et al. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab. 2015;116(4):298\u2013304. https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.010.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3889_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/WNF.0b013e318288076a","volume":"36","author":"G Yahalom","year":"2013","unstructured":"Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013;36(3):78\u201383. https:\/\/doi.org\/10.1097\/WNF.0b013e318288076a.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"3889_CR19","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1468-1331.2011.03439.x","volume":"18","author":"B Pilo-de-la-Fuente","year":"2011","unstructured":"Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18(10):1203\u201311. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03439.x.","journal-title":"Eur J Neurol"},{"issue":"Suppl 2","key":"3889_CR20","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s10545-008-0815-z","volume":"31","author":"G Pierre","year":"2008","unstructured":"Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis. 2008;31(Suppl 2):S241\u20135. https:\/\/doi.org\/10.1007\/s10545-008-0815-z.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"3889_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0009-8981(85)90182-2","volume":"152","author":"BJ Koopman","year":"1985","unstructured":"Koopman BJ, Wolthers BG, van der Molen JC, Waterreus RJ. Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. Clin Chim Acta. 1985;152(1\u20132):115\u201322. https:\/\/doi.org\/10.1016\/0009-8981(85)90182-2.","journal-title":"Clin Chim Acta"},{"issue":"8","key":"3889_CR22","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00415-019-09377-y","volume":"266","author":"D Mandia","year":"2019","unstructured":"Mandia D, Chaussenot A, Besson G, et al. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol. 2019;266(8):2043\u201350. https:\/\/doi.org\/10.1007\/s00415-019-09377-y.","journal-title":"J Neurol"},{"issue":"1","key":"3889_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","volume":"1","author":"JYL Chiang","year":"2017","unstructured":"Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 2017;1(1):3\u20139. https:\/\/doi.org\/10.1016\/j.livres.2017.05.001.","journal-title":"Liver Res"},{"issue":"2","key":"3889_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1194\/jlr.M400256-JLR200","volume":"46","author":"A Honda","year":"2005","unstructured":"Honda A, Salen G, Matsuzaki Y, et al. Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis. J Lipid Res. 2005;46(2):287\u201396. https:\/\/doi.org\/10.1194\/jlr.M400256-JLR200.","journal-title":"J Lipid Res"},{"key":"3889_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.apha.2015.04.003","volume":"74","author":"T Li","year":"2015","unstructured":"Li T, Apte U. Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. Adv Pharmacol. 2015;74:263\u2013302. https:\/\/doi.org\/10.1016\/bs.apha.2015.04.003.","journal-title":"Adv Pharmacol"},{"issue":"1","key":"3889_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","volume":"582","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 2008;582(1):10\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.015.","journal-title":"FEBS Lett"},{"issue":"Suppl 1","key":"3889_CR27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.freeradbiomed.2014.10.594","volume":"75","author":"F Bellanti","year":"2014","unstructured":"Bellanti F, Mitarotonda D, Tamborra R, et al. Oxysterols induce mitochondrial impairment and hepatocellular toxicity in non-alcoholic fatty liver disease. Free Radic Biol Med. 2014;75(Suppl 1):S16\u20137. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2014.10.594.","journal-title":"Free Radic Biol Med"},{"key":"3889_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.redox.2017.11.016","volume":"15","author":"F Bellanti","year":"2018","unstructured":"Bellanti F, Villani R, Tamborra R, et al. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression. Redox Biol. 2018;15:86\u201396. https:\/\/doi.org\/10.1016\/j.redox.2017.11.016.","journal-title":"Redox Biol"},{"issue":"3","key":"3889_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MPG.0000000000001657","volume":"65","author":"JE Heubi","year":"2017","unstructured":"Heubi JE, Bove KE, Setchell KDR. Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and zellweger spectrum disorders. J Pediatr Gastroenterol Nutr. 2017;65(3):321\u20136. https:\/\/doi.org\/10.1097\/MPG.0000000000001657.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"3889_CR30","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1053\/j.gastro.2009.07.043","volume":"137","author":"E Gonzales","year":"2009","unstructured":"Gonzales E, Gerhardt MF, Fabre M, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology. 2009;137(4):1310\u201320. https:\/\/doi.org\/10.1053\/j.gastro.2009.07.043.","journal-title":"Gastroenterology"},{"key":"3889_CR31","unstructured":"Cholic Acid Orphacol: EPAR - Product Information. 2013;"},{"issue":"3","key":"3889_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0303-8467(87)80050-1","volume":"89","author":"RJ Waterreus","year":"1987","unstructured":"Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. Clin Neurol Neurosurg. 1987;89(3):169\u201375. https:\/\/doi.org\/10.1016\/s0303-8467(87)80050-1.","journal-title":"Clin Neurol Neurosurg"},{"key":"3889_CR33","unstructured":"Cholic Acid Kolbam: EPAR - Product Information. European Medicines Agency; 2015."},{"issue":"6","key":"3889_CR34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/MPG.0000000000001734","volume":"65","author":"AA Al-Hussaini","year":"2017","unstructured":"Al-Hussaini AA, Setchell KDR, AlSaleem B, et al. Bile acid synthesis disorders in arabs: a 10-year screening study. J Pediatr Gastroenterol Nutr. 2017;65(6):613\u201320. https:\/\/doi.org\/10.1097\/MPG.0000000000001734.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"26","key":"3889_CR35","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJM198412273112601","volume":"311","author":"VM Berginer","year":"1984","unstructured":"Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311(26):1649\u201352. https:\/\/doi.org\/10.1056\/NEJM198412273112601.","journal-title":"N Engl J Med"},{"issue":"8","key":"3889_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/ncpgasthep1179","volume":"5","author":"SS Sundaram","year":"2008","unstructured":"Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol. 2008;5(8):456\u201368. https:\/\/doi.org\/10.1038\/ncpgasthep1179.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"22","key":"3889_CR37","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","volume":"159","author":"AF Hofmann","year":"1999","unstructured":"Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159(22):2647\u201358. https:\/\/doi.org\/10.1001\/archinte.159.22.2647.","journal-title":"Arch Intern Med"},{"issue":"8","key":"3889_CR38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/j.1651-2227.1996.tb14189.x","volume":"85","author":"AF van Heijst","year":"1996","unstructured":"van Heijst AF, Wevers RA, Tangerman A, Cruysberg JR, Renier WO, Tolboom JJ. Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr. 1996;85(8):932\u20136. https:\/\/doi.org\/10.1111\/j.1651-2227.1996.tb14189.x.","journal-title":"Acta Paediatr"},{"issue":"4","key":"3889_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10024-002-1201-8","volume":"7","author":"KE Bove","year":"2004","unstructured":"Bove KE, Heubi JE, Balistreri WF, Setchell KD. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol Jul-Aug. 2004;7(4):315\u201334. https:\/\/doi.org\/10.1007\/s10024-002-1201-8.","journal-title":"Pediatr Dev Pathol Jul-Aug"},{"issue":"3","key":"3889_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1503\/cmaj.1040752","volume":"172","author":"EG Giannini","year":"2005","unstructured":"Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367\u201379. https:\/\/doi.org\/10.1503\/cmaj.1040752.","journal-title":"CMAJ"},{"issue":"12","key":"3889_CR41","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1039\/c7md00475c","volume":"8","author":"S Kundu","year":"2017","unstructured":"Kundu S, Bansal S, Muthukumarasamy KM, Sachidanandan C, Motiani RK, Bajaj A. Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using in vitro and in vivo model systems. Medchemcomm. 2017;8(12):2248\u201357. https:\/\/doi.org\/10.1039\/c7md00475c.","journal-title":"Medchemcomm"},{"issue":"5","key":"3889_CR42","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacl.2018.06.008","volume":"12","author":"PB Duell","year":"2018","unstructured":"Duell PB, Salen G, Eichler FS, et al. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol Sep-Oct. 2018;12(5):1169\u201378. https:\/\/doi.org\/10.1016\/j.jacl.2018.06.008.","journal-title":"J Clin Lipidol Sep-Oct"},{"issue":"4","key":"3889_CR43","first-page":"428","volume":"46","author":"K Miyai","year":"1982","unstructured":"Miyai K, Javitt NB, Gochman N, Jones HM, Baker D. Hepatotoxicity of bile acids in rabbits: ursodeoxycholic acid is less toxic than chenodeoxycholic acid. Lab Invest. 1982;46(4):428\u201337.","journal-title":"Lab Invest"},{"key":"3889_CR44","unstructured":"Chenodeoxycholic Acid Leadiant: EPAR- Product Information. European Medicines Agency; 2017."},{"issue":"2","key":"3889_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00424-018-2223-z","volume":"471","author":"P Lenzig","year":"2019","unstructured":"Lenzig P, Wirtz M, Wiemuth D. Comparative electrophysiological analysis of the bile acid-sensitive ion channel (BASIC) from different species suggests similar physiological functions. Pflugers Arch. 2019;471(2):329\u201336. https:\/\/doi.org\/10.1007\/s00424-018-2223-z.","journal-title":"Pflugers Arch"},{"issue":"3","key":"3889_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1085\/jgp.20028537","volume":"119","author":"AM Dopico","year":"2002","unstructured":"Dopico AM, Walsh JV Jr, Singer JJ. Natural bile acids and synthetic analogues modulate large conductance Ca2+-activated K+ (BKCa) channel activity in smooth muscle cells. J Gen Physiol. 2002;119(3):251\u201373. https:\/\/doi.org\/10.1085\/jgp.20028537.","journal-title":"J Gen Physiol"},{"issue":"2","key":"3889_CR47","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.neulet.2011.11.036","volume":"506","author":"SR Schubring","year":"2012","unstructured":"Schubring SR, Fleischer W, Lin JS, Haas HL, Sergeeva OA. The bile steroid chenodeoxycholate is a potent antagonist at NMDA and GABA(A) receptors. Neurosci Lett. 2012;506(2):322\u20136. https:\/\/doi.org\/10.1016\/j.neulet.2011.11.036.","journal-title":"Neurosci Lett"},{"key":"3889_CR48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fnins.2017.00617","volume":"11","author":"KL Mertens","year":"2017","unstructured":"Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front Neurosci. 2017;11:617. https:\/\/doi.org\/10.3389\/fnins.2017.00617.","journal-title":"Front Neurosci"},{"key":"3889_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0070-2153(07)80004-4","volume":"80","author":"DE Westholm","year":"2008","unstructured":"Westholm DE, Rumbley JN, Salo DR, Rich TP, Anderson GW. Organic anion-transporting polypeptides at the blood-brain and blood-cerebrospinal fluid barriers. Curr Top Dev Biol. 2008;80:135\u201370. https:\/\/doi.org\/10.1016\/S0070-2153(07)80004-4.","journal-title":"Curr Top Dev Biol"},{"key":"3889_CR50","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ebiom.2018.10.030","volume":"37","author":"G Xie","year":"2018","unstructured":"Xie G, Wang X, Jiang R, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018;37:294\u2013306. https:\/\/doi.org\/10.1016\/j.ebiom.2018.10.030.","journal-title":"EBioMedicine"},{"issue":"2","key":"3889_CR51","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1517\/17425255.1.2.233","volume":"1","author":"JM Scherrmann","year":"2005","unstructured":"Scherrmann JM. Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin Drug Metab Toxicol. 2005;1(2):233\u201346. https:\/\/doi.org\/10.1517\/17425255.1.2.233.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"41","key":"3889_CR52","doi-asserted-by":"publisher","first-page":"11074","DOI":"10.1021\/bi00092a017","volume":"32","author":"F Kamp","year":"1993","unstructured":"Kamp F, Hamilton JA, Kamp F, Westerhoff HV, Hamilton JA. Movement of fatty acids, fatty acid analogues, and bile acids across phospholipid bilayers. Biochemistry. 1993;32(41):11074\u201386. https:\/\/doi.org\/10.1021\/bi00092a017.","journal-title":"Biochemistry"},{"key":"3889_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.steroids.2017.07.001","volume":"125","author":"T Higashi","year":"2017","unstructured":"Higashi T, Watanabe S, Tomaru K, et al. Unconjugated bile acids in rat brain: Analytical method based on LC\/ESI-MS\/MS with chemical derivatization and estimation of their origin by comparison to serum levels. Steroids. 2017;125:107\u201313. https:\/\/doi.org\/10.1016\/j.steroids.2017.07.001.","journal-title":"Steroids"},{"key":"3889_CR54","doi-asserted-by":"publisher","first-page":"175726","DOI":"10.1016\/j.ejphar.2023.175726","volume":"949","author":"MS Alavi","year":"2023","unstructured":"Alavi MS, Karimi G, Ghanimi HA, Roohbakhsh A. The potential of CYP46A1 as a novel therapeutic target for neurological disorders: an updated review of mechanisms. Eur J Pharmacol. 2023;949:175726. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175726.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"3889_CR55","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1194\/jlr.M008326","volume":"51","author":"A Bavner","year":"2010","unstructured":"Bavner A, Shafaati M, Hansson M, et al. On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. J Lipid Res. 2010;51(9):2722\u201330. https:\/\/doi.org\/10.1194\/jlr.M008326.","journal-title":"J Lipid Res"},{"issue":"4","key":"3889_CR56","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MOL.0b013e328362df13","volume":"24","author":"I Bjorkhem","year":"2013","unstructured":"Bjorkhem I. Cerebrotendinous xanthomatosis. Curr Opin Lipidol. 2013;24(4):283\u20137. https:\/\/doi.org\/10.1097\/MOL.0b013e328362df13.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"3889_CR57","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1194\/jlr.M700027-JLR200","volume":"48","author":"U Panzenboeck","year":"2007","unstructured":"Panzenboeck U, Andersson U, Hansson M, Sattler W, Meaney S, Bjorkhem I. On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J Lipid Res. 2007;48(5):1167\u201374. https:\/\/doi.org\/10.1194\/jlr.M700027-JLR200.","journal-title":"J Lipid Res"},{"issue":"1","key":"3889_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archneur.1968.00480010065004","volume":"19","author":"JH Menkes","year":"1968","unstructured":"Menkes JH, Schimschock JR, Swanson PD. Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol. 1968;19(1):47\u201353. https:\/\/doi.org\/10.1001\/archneur.1968.00480010065004.","journal-title":"Arch Neurol"},{"issue":"3","key":"3889_CR59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s10038-017-0389-4","volume":"63","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Koyama S, Yoshinaga T, Koinuma M, Inaba Y. Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet. 2018;63(3):271\u201380. https:\/\/doi.org\/10.1038\/s10038-017-0389-4.","journal-title":"J Hum Genet"},{"issue":"2","key":"3889_CR60","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000006731","volume":"92","author":"BML Stelten","year":"2019","unstructured":"Stelten BML, Huidekoper HH, van de Warrenburg BPC, et al. Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology. 2019;92(2):e83\u201395. https:\/\/doi.org\/10.1212\/WNL.0000000000006731.","journal-title":"Neurology"},{"issue":"5","key":"3889_CR61","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10545-018-0162-7","volume":"41","author":"MDM Amador","year":"2018","unstructured":"Amador MDM, Masingue M, Debs R, et al. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes. J Inherit Metab Dis. 2018;41(5):799\u2013807.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3889_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10545-015-9873-1","volume":"39","author":"A Mignarri","year":"2016","unstructured":"Mignarri A, Magni A, Del Puppo M, et al. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2016;39(1):75\u201383. https:\/\/doi.org\/10.1007\/s10545-015-9873-1.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3889_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0006-2944(75)90020-4","volume":"14","author":"G Salen","year":"1975","unstructured":"Salen G, Meriwether TW, Nicolau G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med. 1975;14(1):57\u201374. https:\/\/doi.org\/10.1016\/0006-2944(75)90020-4.","journal-title":"Biochem Med"},{"issue":"3","key":"3889_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/BF00314598","volume":"237","author":"M Donaghy","year":"1990","unstructured":"Donaghy M, King RH, McKeran RO, Schwartz MS, Thomas PK. Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid. J Neurol. 1990;237(3):216\u20139. https:\/\/doi.org\/10.1007\/BF00314598.","journal-title":"J Neurol"},{"issue":"3","key":"3889_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00223-012-9677-3","volume":"92","author":"G Martini","year":"2013","unstructured":"Martini G, Mignarri A, Ruvio M, et al. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int. 2013;92(3):282\u20136. https:\/\/doi.org\/10.1007\/s00223-012-9677-3.","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"3889_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6661","volume":"10","author":"N Karimi","year":"2022","unstructured":"Karimi N, Amiri Z, Naeini S, Okhovat AA. Cerebrotendinous xanthomatosis and infertility: a case report. Clin Case Rep. 2022;10(12): e6661. https:\/\/doi.org\/10.1002\/ccr3.6661.","journal-title":"Clin Case Rep"},{"issue":"11","key":"3889_CR67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s004150050274","volume":"245","author":"MT Dotti","year":"1998","unstructured":"Dotti MT, Mondillo S, Plewnia K, Agricola E, Federico A. Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. J Neurol. 1998;245(11):723\u20136. https:\/\/doi.org\/10.1007\/s004150050274.","journal-title":"J Neurol"},{"issue":"3","key":"3889_CR68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0009-8981(90)90242-k","volume":"193","author":"BG Wolthers","year":"1990","unstructured":"Wolthers BG, van der Molen JC, Walrecht H, Hesselmans LF. Reduction of urinary bile alcohol excretion and serum cholestanol in patients with cerebrotendinous xanthomatosis after oral administration of deoxycholic acid. Clin Chim Acta. 1990;193(3):113\u20138. https:\/\/doi.org\/10.1016\/0009-8981(90)90242-k.","journal-title":"Clin Chim Acta"},{"key":"3889_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101449","author":"YY Kisanuki","year":"2025","unstructured":"Kisanuki YY, Nobrega PR, Himes R, et al. Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): a randomized withdrawal, double-blind, placebo-controlled, crossover phase 3 study. Genet Med. 2025. https:\/\/doi.org\/10.1016\/j.gim.2025.101449.","journal-title":"Genet Med"},{"issue":"3","key":"3889_CR70","first-page":"193","volume":"20","author":"S Potin","year":"2001","unstructured":"Potin S, Desroches M-C, Casaurang M, et al. Bile acid synthesis defects treatment evaluation by cholic acid and\/or ursodeoxycholic acid in a pediatric clinical trial. J Pharm Clin. 2001;20(3):193\u20136.","journal-title":"J Pharm Clin"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03889-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:52:40Z","timestamp":1757314360000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03889-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3889"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03889-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Asklepion Pharmaceuticals LLC receives royalties from Mirum Pharmaceuticals. JC is Chief Executive Officer, and GK is Chief Medical Officer at Asklepion Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}